PAPILLON Final Survival Analysis Requires Crossover Context
The final overall-survival analysis of PAPILLON reported median survival of 34.3 months with first-line amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone, but the intent-to-treat comparison was not statistically significant (HR 0.87; P=0.307)….
